2'-岩藻糖基乳糖预防婴幼儿坏死性小肠结肠炎及感染性腹泻的研究进展

陆梦兰 陈财龙 徐加英 石羽杰 苏红文 刘彪 秦立强

陆梦兰,陈财龙,徐加英,等. 2'-岩藻糖基乳糖预防婴幼儿坏死性小肠结肠炎及感染性腹泻的研究进展[J]. 食品工业科技,2021,42(23):408−412. doi:  10.13386/j.issn1002-0306.2020100239
引用本文: 陆梦兰,陈财龙,徐加英,等. 2'-岩藻糖基乳糖预防婴幼儿坏死性小肠结肠炎及感染性腹泻的研究进展[J]. 食品工业科技,2021,42(23):408−412. doi:  10.13386/j.issn1002-0306.2020100239
LU Menglan, CHEN Cailong, XU Jiaying, et al. Protective Effect of 2'-Fucosyllactose on Necrotizing Enterocolitis and Infectious Diarrhea in Infants[J]. Science and Technology of Food Industry, 2021, 42(23): 408−412. (in Chinese with English abstract). doi:  10.13386/j.issn1002-0306.2020100239
Citation: LU Menglan, CHEN Cailong, XU Jiaying, et al. Protective Effect of 2'-Fucosyllactose on Necrotizing Enterocolitis and Infectious Diarrhea in Infants[J]. Science and Technology of Food Industry, 2021, 42(23): 408−412. (in Chinese with English abstract). doi:  10.13386/j.issn1002-0306.2020100239

2'-岩藻糖基乳糖预防婴幼儿坏死性小肠结肠炎及感染性腹泻的研究进展

doi: 10.13386/j.issn1002-0306.2020100239
详细信息
    作者简介:

    陆梦兰(1996−),女,硕士研究生,研究方向:营养与疾病,E-mail:lumenglan@126.com

    通讯作者:

    秦立强(1970−),男,博士,教授,研究方向:营养与疾病,E-mail: qinliqiang@suda.edu.cn

  • 中图分类号: R15

Protective Effect of 2'-Fucosyllactose on Necrotizing Enterocolitis and Infectious Diarrhea in Infants

  • 摘要: 婴幼儿尤其是新生儿消化和免疫功能不全、肠道发育不成熟,导致肠道耐受性差和细菌定植困难,并对坏死性小肠结肠炎和感染性腹泻高度敏感。母乳喂养对婴幼儿肠道健康的益处有赖于母乳中特殊的低聚糖,2'-岩藻糖基乳糖是母乳中含量较高的低聚糖。本文综述了2'-岩藻糖基乳糖的安全性,对肠道菌群及免疫系统的调节,以及对预防婴幼儿坏死性小肠结肠炎和感染性腹泻作用的研究进展。
  • [1] BODE L. Human milk oligosaccharides: Every baby needs a sugar mama[J]. Glycobiology,2012,22(9):1147−1162. doi:  10.1093/glycob/cws074
    [2] VANDENPLAS Y, BERGER B, CARNIELLI V P, et al. Human milk oligosaccharides: 2'-fucosyllactose (2’-FL) and Lacto-N-Neotetraose (LNnT) in infant formula[J]. Nutrients,2018,10(9):1161. doi:  10.3390/nu10091161
    [3] KONG C L, FAAS MM, DEVOS P, et al. Impact of dietary fibers in infant formulas on gut microbiota and the intestinal immune barrier[J]. Food & Function,2020,11(11):9445−9467.
    [4] PATEL R M, DENNING P W. Intestinal microbiota and its relationship with necrotizing enterocolitis[J]. Pediatric Research,2015,78(3):232−238. doi:  10.1038/pr.2015.97
    [5] BERING S B. Human milk oligosaccharides to prevent gut dysfunction and necrotizing enterocolitis in preterm neonates[J]. Nutrients,2018,10(10):1461. doi:  10.3390/nu10101461
    [6] SAMUEL T M, BINIA A, DE CASTRO C A, et al. Impact of maternal characteristics on human milk oligosaccharide composition over the first 4 months of lactation in a cohort of healthy European mothers[J]. Scientific Reports,2019,9(1):11767. doi:  10.1038/s41598-019-48337-4
    [7] YAN J, DING J, JIN G, et al. Profiling of human milk oligosaccharides for Lewis epitopes and secretor status by electrostatic repulsion hydrophilic interaction chromatography coupled with negative-Ion electrospray tandem mass spectrometry[J]. Analytical Chemistry,2019,91(13):8199−8206. doi:  10.1021/acs.analchem.9b00687
    [8] LEFEBVRE G, SHEVLYAKOVA M, CHARPAGNE A, et al. Time of lactation and maternal fucosyltransferase genetic polymorphisms determine the variability in human milk oligosaccharides[J]. Frontiers in Nutrition,2020,7:574459. doi:  10.3389/fnut.2020.574459
    [9] COULET M, PHOTHIRATH P, ALLAIS L, et al. Pre-clinical safety evaluation of the synthetic human milk, nature-identical, oligosaccharide 2′-O-fucosyllactose (2′FL)[J]. Regulatory Toxicology and Pharmacology,2014,68(1):59−69. doi:  10.1016/j.yrtph.2013.11.005
    [10] 潘丽娜, 李泽, 郁欢欢, 等. 配方奶粉中添加2'-岩藻糖基乳糖对小鼠消化吸收功能影响[J]. 中国乳品工业,2019,47(10):20−23. [PAN L N, LI Z, YU H H, et al. Effect of 2' -fucosyllactose added to formula milk powder on digestion and absorption function of mice[J]. Chinese Dairy Industry,2019,47(10):20−23. doi:  10.3969/j.issn.1001-2230.2019.10.004
    [11] MARRIAGE B J, BUCK R H, GOEHRING K C, et al. Infants fed a lower calorie formula with 2'-FL show growth and 2'-FL uptake like breast-fed infants[J]. Journal of Pediatric Gastroenterology and Nutrition,2015,61(6):649−658. doi:  10.1097/MPG.0000000000000889
    [12] JUNG S M, CHIN Y W, LEE Y G, et al. Enhanced production of 2'-fucosyllactose from fucose by elimination of rhamnose isomerase and arabinose isomerase in engineered Escherichia coli[J]. Biotechnology and Bioengineering,2019,116(9):2412−2417. doi:  10.1002/bit.27019
    [13] SPRENGER G A, BAUMGARTNER F, ALBERMANN C. Production of human milk oligosaccharides by enzymatic and whole-cell microbial biotransformations[J]. Journal of Biotechnology,2017,258:79−91. doi:  10.1016/j.jbiotec.2017.07.030
    [14] PEREZ-ESCALANTE E, ALATORRE-SANTAMARIA S, CASTANEDA-OVANDO A, et al. Human milk oligosaccharides as bioactive compounds in infant formula: Recent advances and trends in synthetic methods[J]. Critical Reviews in Food Science and Nutrition,2020:1−34.
    [15] SALMINEN S. Regulatory aspects of human milk oligosaccharides[J]. Nestle Nutrition Institute Workshop Series,2017,88:161−170.
    [16] TURCK D, CASTENMILLER J, DE HENAUW S, et al. Safety of 2'-fucosyllactose/difucosyllactose mixture as a novel food pursuant to Regulation (EU) 2015/2283[J]. EFSA Journal European Food Safety Authority,2019,17(6):e05717.
    [17] HOLSCHER HD, BODE L, TAPPENDEN KA. Human milk oligosaccharides influence intestinal epithelial cell maturation in vitro[J]. Journal of Pediatric Gastroenterology and Nutrition,2017,64(2):296−301. doi:  10.1097/MPG.0000000000001274
    [18] AZAGRA-BORONAT I, MASSOT-CLADERA M, MAYNERIS-PERXACHS J, et al. Immunomodulatory and prebiotic effects of 2'-Fucosyllactose in suckling rats[J]. Frontiers in Immunology,2019,10:1773−1773. doi:  10.3389/fimmu.2019.01773
    [19] CHLEILAT F, KLANCIC T, MA K, et al. Human milk oligosaccharide supplementation affects intestinal barrier function and microbial composition in the gastrointestinal tract of young sprague Dawley rats[J]. Nutrients,2020,12(5):1532.
    [20] GALAZZO G, VAN BEST N, BERVOETS L, et al. Development of the microbiota and associations with birth mode, diet, and atopic disorders in a longitudinal analysis of stool samples, collected from infancy through early childhood[J]. Gastroenterology,2020,158(6):1584−1596. doi:  10.1053/j.gastro.2020.01.024
    [21] LUGLI GA, DURANTI S, MILANI C, et al. Investigating bifidobacteria and human milk oligosaccharide composition of lactating mothers[J]. FEMS Microbiology Ecology,2020,96(5):fiaa049. doi:  10.1093/femsec/fiaa049
    [22] PAMMI M, COPE J, TARR PI, et al. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: A systematic review and meta-analysis[J]. Microbiome,2017,5(1):31. doi:  10.1186/s40168-017-0248-8
    [23] ZHANG G, ZHAO J, WEN R, et al. 2'-Fucosyllactose promotes bifidobacterium bifidum DNG6 adhesion to Caco-2 cells[J]. Journal of Dairy Science,2020,103(11):9825−9834. doi:  10.3168/jds.2020-18773
    [24] SALLI K, ANGLENIUS H, HIRONEN J, et al. The effect of 2'-fucosyllactose on simulated infant gut microbiome and metabolites; a pilot study in comparison to GOS and lactose[J]. Scientific Reports,2019,9(1):13232. doi:  10.1038/s41598-019-49497-z
    [25] SALLI K, HIRVONEN J, SIITONEN J, et al. Selective utilization of the hman milk oligosaccharides 2'-Fucosyllactose, 3'-Fucosyllactose, and difucosyllactose by various probiotic and pathogenic bacteria[J]. Journal of Agricultural and Food Chemistry,2021,69(1):170−182. doi:  10.1021/acs.jafc.0c06041
    [26] HOLACHER H D. Dietary fiber and prebiotics and the gastrointestinal microbiota[J]. Gut Microbes,2017,8(2):172−184. doi:  10.1080/19490976.2017.1290756
    [27] LANGHORST J, KOCH A K, VOISS P, et al. Distinct patterns of short-chain fatty acids during flare in patients with ulcerative colitis under treatment with mesalamine or a herbal combination of myrrh, chamomile flowers, and coffee charcoal: Secondary analysis of a randomized controlled trial[J]. European Journal of Gastroenterology & Hepatology,2020,32(2):175−180.
    [28] HOEFLINGER J L, DAVIS S R, CHOW J, et al. In vitro impact of human milk oligosaccharides on Enterobacteriaceae growth[J]. Journal of Agricultural and Food Chemistry,2015,63(12):3295−3302. doi:  10.1021/jf505721p
    [29] MEDINA D A, PINTO F, ORTUZAR V, et al. Simulation and modeling of dietary changes in the infant gut microbiome[J]. FEMS Microbiology Ecology,2018,94(9).
    [30] SHOKRYAZDAN P, FASELEH JAHROMI M, NAVIDSHAD B, et al. Effects of prebiotics on immune system and cytokine expression[J]. Medical Microbiology and Immunology,2017,206(1):1−9. doi:  10.1007/s00430-016-0481-y
    [31] DONOVAN SM, COMSTOCK SS. Human milk oligosaccharides influence neonatal mucosal and systemic immunity[J]. Annals of Nutrition & Metabolism,2016,69 Suppl 2(Suppl2):42−51.
    [32] CASTILLO-COURTADE L, HAN S, LEE S, et al. Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse model[J]. Allergy,2015,70(9):1091−1102. doi:  10.1111/all.12650
    [33] NOLL AJ, YU Y, LASANAJAK Y, et al. Human DC-SIGN binds specific human milk glycans[J]. The Biochemical Journal,2016,473(10):1343−1353. doi:  10.1042/BCJ20160046
    [34] AYECHU-MURUZABAL V, OVERBEEK SA, KOSTADINOVA AI, et al. Exposure of intestinal epithelial cells to 2'-Fucosyllactose and CpG enhances galectin release and instructs dendritic cells to drive Th1 and regulatory-type immune development[J]. Biomolecules,2020,10(5):784. doi:  10.3390/biom10050784
    [35] HE Y, LIU S, KLING DE, et al. The human milk oligosaccharide 2'-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation[J]. Gut,2016,65(1):33−46. doi:  10.1136/gutjnl-2014-307544
    [36] XIAO L, LEUSINK-MUIS T, KETTELARIJ N, et al. Human milk oligosaccharide 2'-fucosyllactose improves innate and adaptive immunity in an influenza-specific murine vaccination model[J]. Frontiers in Immunology,2018,9:452. doi:  10.3389/fimmu.2018.00452
    [37] PATEL A L, PANAGOS P G, SILVESTRI J M. Reducing incidence of necrotizing enterocolitis[J]. Clinics in Perinatology,2017,44(3):683−700. doi:  10.1016/j.clp.2017.05.004
    [38] WEJRYD E, MARTI M, MARCHINI G, et al. Low diversity of human milk oligosaccharides is associated with necrotising enterocolitis in extremely low birth weight infants[J]. Nutrients,2018,10(10):1556. doi:  10.3390/nu10101556
    [39] LIN P W, STOLL B J. Necrotising enterocolitis[J]. The Lancet,2006,368(9543):1271−1283. doi:  10.1016/S0140-6736(06)69525-1
    [40] NINO D F, SODHI C P, HACKAM D J. Necrotizing enterocolitis: New insights into pathogenesis and mechanisms[J]. Nature Reviews Gastroenterology & Hepatology,2016,13(10):590−600.
    [41] ROZE JC, ANCEL PY, LEPAGE P, et al. Nutritional strategies and gut microbiota composition as risk factors for necrotizing enterocolitis in very-preterm infants[J]. American Journalof Clinical Nutrition,2017,106(3):821−830. doi:  10.3945/ajcn.117.152967
    [42] SODHI C P, WIPF P, YAMAGUCHI Y, et al. The human milk oligosaccharides 2'-fucosyllactose and 6'-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling[J]. Pediatric Research,2020,10:1038.
    [43] GOOD M, SODHI C P, YAMAGUCHI Y, et al. The human milk oligosaccharide 2'-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestine[J]. British Journal of Nutrition,2016,116(7):1175−1187. doi:  10.1017/S0007114516002944
    [44] WANG C, ZHANG M, GUO H, et al. Human milk oligosaccharides protect against necrotizing enterocolitis by inhibiting intestinal damage via increasing the proliferation of Crypt cells[J]. Molecular Nutrition & Food Research,2019,63(18):1900262.
    [45] AUTRAN CA, SCHOTERMAN MH, JANTSCHER-KREEN E, et al. Sialylated galacto-oligosaccharides and 2'-fucosyllactose reduce necrotising enterocolitis in neonatal rats[J]. British Journal of Nutrition,2016,116(2):294−299. doi:  10.1017/S0007114516002038
    [46] CILIEBORG MS, BERING SB, ØSTERGAARD MV, et al. Minimal short-term effect of dietary 2'-fucosyllactose on bacterial colonisation, intestinal function and necrotising enterocolitis in preterm pigs[J]. British Journal of Nutrition,2016,116(5):834−841. doi:  10.1017/S0007114516002646
    [47] AUTARN C A, KELLMAN B P, KIM J H, et al. Human milk oligosaccharide composition predicts risk of necrotising enterocolitis in preterm infants[J]. Gut,2018,67(6):1064−1070. doi:  10.1136/gutjnl-2016-312819
    [48] KOTLOFF KL, NASRIN D, BLACKWELDER WC, et al. The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: A 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS)[J]. Lancet Global Health,2019,7(5):e568−e584. doi:  10.1016/S2214-109X(19)30076-2
    [49] WANG Y, ZOU Y, WANG J, et al. The protective effects of 2'-fucosyllactose against E. Coli O157 infection are mediated by the regulation of gut microbiota and the inhibition of pathogen adhesion[J]. Nutrients,2020,12(5):1284. doi:  10.3390/nu12051284
    [50] CILIEBORG M S, SANGILD P T, JENSEN M L, et al. α1, 2-Fucosyllactose does not improve intestinal function or prevent escherichia coli F18 diarrhea in newborn pigs[J]. Journal of Pediatric Gastroenterology and Nutrition,2017,64(2):310−318. doi:  10.1097/MPG.0000000000001276
    [51] MORROW A L, RUIZ-PALACIOS G M, et al. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea[J]. Journal of Nutrition,2005,135(5):1304−1307. doi:  10.1093/jn/135.5.1304
    [52] YU Z T, NANTHAKUMAR N N, NEWBURG D S. The human milk oligosaccharide 2'-Fucosyllactose quenches campylobacter jejuni-induced inflammation in human epithelial cells HEp-2 and HT-29 and in mouse intestinal mucosa[J]. Journal of Nutrition,2016,146(10):1980−1990. doi:  10.3945/jn.116.230706
    [53] SCHROTEN H, HANISCH F G, HANSMAN G S. Human norovirus interactions with Histo-Blood group antigens and human milk oligosaccharides[J]. Journal of Virology,2016,90(13):5855−5859. doi:  10.1128/JVI.00317-16
    [54] LAUCIRICA D R, TRIANTIS V, SCHOEMAKER R, et al. Milk oligosaccharides inhibit human rotavirus infectivity in MA104 cells[J]. Journal of Nutrition,2017,147(9):1709−1714.
    [55] NATIVIDAD J M, RYTZ A, KEDDANI S, et al. Blends of human milk oligosaccharides confer intestinal epithelial barrier protection in vitro[J]. Nutrients,2020,12(10):3047. doi:  10.3390/nu12103047
  • 加载中
计量
  • 文章访问数:  25
  • HTML全文浏览量:  8
  • PDF下载量:  4
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-10-29
  • 网络出版日期:  2021-10-21
  • 刊出日期:  2021-12-01

目录

    /

    返回文章
    返回

    重要通知

    喜报:《食品工业科技》2021版影响因子稳居第二,且影响因子大幅提升